Abstract
The maximal proteolytic activity that can be generated in plasma with the inhibitors present is termed proteolytic capacity, and it has previously been shown that a marked inter-individual variation exists. By testing many normal persons several times, it was demonstrated that each individual has a rather stable level of proteolytic capacity. In family studies it was shown that the property ‘low proteolytic capacity’ (LPC) was inherited as an autosomal dominant trait. The property ‘high proteolytic capacity’ (HPC) was also genetically determined, but no clear-cut mode of inheritance could be found. Study of monozygotic twins also confirmed that the proteolytic capacity was genetically determined. Increased tendency to thrombosis did not occur in families with LPC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Scandinavian journal of clinical and laboratory investigation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
